Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer.

ABSTRACT:

Background

As one of the many breast cancer subtypes, human epidermal growth factor receptor 2 (Her2)-positive breast cancer has higher invasiveness and poor prognosis, although the advent of anti-Her2 drugs has brought good news to patients. However, the emergence of drug resistance still limits its clinical efficacy, so there is an urgent need to explore new targets and develop a risk scoring system to improve treatments and evaluate patient prognosis.

Methods

Differentially expressed mRNAs associated with Her2-positive breast cancer were screened from a TCGA cohort. The prognostic risk scoring system was constructed according to univariate and Lasso Cox regression model analyses and combined with clinical factors (such as age and TNM) for univariate and multivariate analy

SUBMITTER: Gao C 

PROVIDER: S-EPMC7161270 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature